India Pharma Outlook Team | Thursday, 06 February 2025
AGC Pharma Chemicals, a leader in pharmaceutical manufacturing with more than 40 years of experience in Contract Development Manufacturing Operations (CDMO) for small molecule APIs located in Barcelona (Spain) and Japan, is enhancing its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities in Barcelona to meet the increasing demand for HPAPI. This innovative facility, supported by a major investment, aims to transform API production and establish new global benchmarks in pharmaceutical manufacturing quality.
This strategic improvement finalizes AGC Pharma Chemicals’ complete HPAPI capabilities, creating a holistic, fully integrated containment solution that smoothly links early-phase development with commercial manufacturing. As a CDMO with HPAPI capabilities ranging from grams to tons, AGC has methodically aligned its entire development and production chain to OEB5 standards (0.1–1 µg/m³ during an 8-hour shift), from its new R&D facility through the lab to commercial manufacturing, guaranteeing uniform containment capabilities across the whole process.
“Our comprehensive method illustrates AGC’s dedication to aiding the entire HPAPI development process,” says Akihiro Kadokura, CEO of AGC Pharma Chemicals. "By providing a seamless array of capabilities collectively, we empower our partners to progress their high-potency compounds from initial grams to commercial tons, all within one dependable ecosystem."
This comprehensive improvement of AGC's HPAPI abilities strengthens its role as a reliable partner in the development and production of pharmaceuticals, providing a cohesive solution for progressing high-potency compounds from initial grams to commercial-scale tons.